Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Beta Bionics (BBNX) over the last 3 years, with Q1 2025 value amounting to $12.4 million.

  • Beta Bionics' Gains from Investment Securities rose 20079.73% to $12.4 million in Q1 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year change of. This contributed to the annual value of $5.7 million for FY2024, which is 893.06% up from last year.
  • According to the latest figures from Q1 2025, Beta Bionics' Gains from Investment Securities is $12.4 million, which was up 20079.73% from $6.0 million recorded in Q4 2024.
  • In the past 5 years, Beta Bionics' Gains from Investment Securities ranged from a high of $12.4 million in Q1 2025 and a low of -$419000.0 during Q3 2024
  • Its 3-year average for Gains from Investment Securities is $5.2 million, with a median of $4.7 million in 2023.
  • In the last 5 years, Beta Bionics' Gains from Investment Securities soared by 1574.3% in 2024 and then skyrocketed by 20079.73% in 2025.
  • Beta Bionics' Gains from Investment Securities (Quarter) stood at $5.2 million in 2023, then grew by 15.74% to $6.0 million in 2024, then surged by 106.74% to $12.4 million in 2025.
  • Its Gains from Investment Securities was $12.4 million in Q1 2025, compared to $6.0 million in Q4 2024 and -$419000.0 in Q3 2024.